Cell therapy weekly: First FDA-monitored clinical trial for the use of stem cells in hypoplastic left heart syndrome patients
This week: Japanese pharma company offers AUS$202 million for Cynata Therapeutics (Australia) and US$3 million grant for research into mesenchymal stem cell-based Alzheimer's therapy.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>